The popular type 2 diabetes drug Onglyza, also known as saxagliptina, has been linked with a significantly increased risk of heart failure.
Oxygen deprivation, or hypoxia, during delivery is a well-known cause for brain damage in infants that can lead to disorders like cerebral palsy. It is also known that low pH levels (high body acid) at birth can lead to complications including brain damage and CP.
Pitocin, made by New Jersey-based JHP Pharmaceuticals, is a synthetic form of the natural hormone oxytocin that regulates uterine contractions.
The rate of knee replacement surgeries each year in the United States has tripled in recent decades to almost 750,000 annually, and the number is expected to continue growing to roughly 3.5 million procedures over the next decade.
Fortunately, American consumers have never had greater access to the civil justice system and the right to seek compensation when harmed by dangerous products. And, with thousands of prescription drugs and medical devices on the market, patients have never faced more harm from side effects.
Coming off a 2016 that saw just over 20 new drugs approved for launch by the FDA, 2017 was a marked improvement - and 2018 looks to be no different. Experts are predicting several of the medications slated for launch next year could become household names.
While type 2 diabetes drugs are among the fastest-growing segment on the market, they’re not without risk of serious side effects. In just the past 5 years, studies have linked them to kidney disease, bladder cancer, pancreatitis and ketoacidosis.
In June, details emerged that DePuy’s Attune knee implant system, one of the most popular on the market, was experiencing higher-than-expected failure rates among patients.
Despite some recent positive results from a small Parkinson’s study, the leukemia medication Tasigna from Swiss drug giant Novartis has been in the news for all the wrong reasons.